Skip to Content
Last Updated: 10/22/2015


The Division of Cancer Treatment and Diagnosis (DCTD) takes prospective detection and treatment leads, facilitates their paths to clinical application, and expedites the initial and subsequent large-scale testing of new agents, biomarkers, imaging tests, and other therapeutic interventions (radiation, surgery, immunotherapy) in patients.

DCTD, like all of NCI, supports many programs that could not be done without government funding — investigators supported by the division engage in scientifically sound, high-risk research that may yield great benefits for patients with cancer, but are too difficult or risky for industry or academia to pursue. This includes a particular emphasis on the development of distinct molecular signatures for cancer, refined molecular assays, and state-of-the-art imaging techniques that will guide oncologic therapy in the future.

The division has eight major programs that work together to bring unique molecules, diagnostic tests, and therapeutic interventions from the laboratory bench to the patient bedside:

The Biometric Research Program provides state-of-the-art statistical, computational, and systems biology analyses for DCTD and other NCI components.

The Cancer Diagnosis Program stimulates, coordinates, and funds specimen resources, databases related to those specimens, and research on diagnostics and improved technologies to better characterize tumors.

The Cancer Imaging Program uses new technologies to expand the role of imaging in noninvasive diagnosis, identification of disease subsets in patients, disease staging, and treatment monitoring.

The Cancer Therapy Evaluation Program functions as NCI's primary clinical evaluator of new anticancer agents, radiation treatments, and surgical methods. The program administers the 11 cooperative research groups that unite researchers around the nation and the world in the pursuit of distinctive and effective new treatments for cancer.

The Developmental Therapeutics Program serves as a vital resource in discovering potential cancer therapeutics and acquiring preclinical development information. The program provides research materials and manufactures new agents in bulk quantities for use in investigational new drug (IND)-directed studies.

The Radiation Research Program provides expertise to investigators who perform novel radiotherapy research and assists in establishing future radiation research directions.

The Translational Research Program translates novel scientific discoveries from the laboratory and/or population studies to the clinic for testing in humans with cancer and determines the biological basis for clinical observations.

The Office of Cancer Complementary and Alternative Medicine aims to increase the amount of high-quality cancer research and information about the use of complementary and alternative modalities.

About the Director

James Doroshow James H. Doroshow, M.D., FACP, has been the Director of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), since 2004. He is responsible for integrating the activities of DCTD with NCI’s other divisions and offices, as well as extramural scientists and clinicians, patient advocates, and professional cancer organizations. More…